Table 1 Patient characteristics
From: Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer
Patient characteristics (TAS cohort, N = 391) | |
|---|---|
Age at study inclusion [years], median (range) | 62 (29–89) |
Weight [kg], median (range) | 66.8 (37–145) |
Sex, n (%) | |
Female | 71 (18) |
Male | 320 (82) |
Location of primary tumora, n (%) | |
Oropharynx | 110 (28) |
Hypopharynx | 94 (24) |
Larynx | 54 (14) |
Oral cavity | 97 (25) |
Other location | 72 (18) |
Prior therapy, n (%) | |
Radiotherapy | 320 (82) |
Surgery | 264 (68) |
Disease progression at study inclusion, n (%) | |
Local recurrence only | 198 (51) |
Distant metastases only | 119 (30) |
Local recurrence and distant metastases | 74 (19) |
Charlson Comorbidity Index at study inclusion, n (%) | |
0 | 188 (48) |
1 | 79 (20) |
> 1 | 124 (32) |
ECOG performance status at treatment initiation, n (%) | |
0 | 65 (17) |
1 | 225 (58) |
≥ 2 | 77 (20) |
Missing | 24 (6) |
Alcohol consumption, n (%) | |
Never | 87 (22) |
Several times per month | 85 (22) |
Several times per week or daily | 101 (26) |
Missing | 118 (30) |
Smoking habits, n (%) | |
Never smoked | 102 (26) |
Former smoker | 148 (38) |
Current smoker | 140 (36) |
Missing | 1 (0) |
Pack years, former and current smoker (n = 288), median (range) | 35 (1–200) |
Applied treatment regimen, n (%) | |
Radiotherapy + cetuximab | 78 (20) |
Chemotherapy + cetuximab | 309 (79) |
Radio-chemotherapy + cetuximab | 4 (1) |
Applied chemotherapy regimen (n = 313), n (%) | |
Cisplatin-based | 174 (56) |
Carboplatin-based | 139 (44) |